Novozymes CFO: By-products and higher prices elevate bioenergy

A great continuance, says CFO, waiving concerns over dwindling bioethanol production output on main US market.
Photo: Pr / Novozymes
Photo: Pr / Novozymes

Sequels rarely compares to originals when talking Hollywood movies. There are, however, a few exceptions. Godfather II springs to mind, as does The Two Towers, Terminator 2, and Q1 of 2023 for the Bioenergy division at Novozymes.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading


See all jobs